Find a Doctor
Klaus H. Kaestner, PhD
Degree and Institution
Ph.D. 1990 Johns Hopkins University School of Medicine
Faculty Title
Professor, Genetics
Department
Genetics
Research Expertise
GI cancer; mouse models.
Other Affiliations
Institute for Diabetes, Obesity and Metabolism
Honors and Awards
Scholarship, German Academic Exchange Service (DAAD)
R. Robert and Sally D. Funderburg Research Scholar Award in Gastric Biology Related to Cancer
Publications
Click here to see my publications
Contact Information
Researcher/Clinician:
Klaus H. Kaestner
Dept. of Genetics
752B CRB
415 Curie Blvd.
Office Phone: 898-8759
Fax: 57305892
Mailing Address:
Klaus H. Kaestner, Ph.D., M.S.
University of Pennsylvania School of Medicine
Dept. of Genetics
752B CRB
415 Curie Blvd.
Philadelphia, PA 19104-6145
Office Phone: 215-898-8759
Appointment Phone: 215-898-8759
Fax: 215-573-5892
Since joining the faculty in 1997 I have contributed substantially to the academic programs of the University of Pennsylvania and the scientific community at large. As an integral member of the mammalian genetics research group and the Penn Diabetes Center and the Penn Center for Molecular Studies in Digestive and Liver Diseases, I have made important contributions in multiple areas including advancing our understanding of the regulation of organ development, glucose homeostasis and transcriptional regulatory networks. My laboratory is focused on the transcriptional regulation of the development and function of the mammalian liver, pancreas and gastrointestinal tract. We are concentrating on the role of the Fox (Forkhead Box) family of transcription factors, and more recently nuclear receptors, in the regulation of these processes. We have demonstrated that targeted inactivation of the mesenchymal factor Foxl1 results in a dramatically altered architecture of the gut epithelium, caused by a substantial increase in cellular proliferation. These findings provided the first genetic evidence for a regulatory cascade between the mesenchyme and the epithelium in the mammalian gut. We have established Foxl1 as the first mesenchymal modifier of the Wnt/APC/?-catenin pathway, which is the main route to colon cancer in humans. This paradigm shift sets the stage for searching for cancer genes in the mesenchymal compartment of the gut, which had been ignored by colon cancer researchers thus far.